Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trials

Louise Taber1 Arizona Research Center, Phoenix, AZ, USA

T Christopher Bond2 Purdue Pharma L.P., Stamford, CT, USACorrespondence[email protected]

Xuezhe Wang2 Purdue Pharma L.P., Stamford, CT, USA

Aditi Kadakia2 Purdue Pharma L.P., Stamford, CT, USA

Tracy J Mayne2 Purdue Pharma L.P., Stamford, CT, USA

References

HYSINGLA ER [webpage on the Internet](hydrocodone bitartrate) extended release tablets for oral use, CII [full prescribing information]Stamford, CTPurdue Pharma L.P.2016 Available from: http://app.purduepharma.com/xmlpublishing/pi.aspx?id=hAccessed 28 March 2017
Google Scholar
WenWSitarSLynchSYHeERipaSRA multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back painExpert Opin Pharmacother201516111593160626111544
PubMed Web of Science ®Google Scholar
WenWTaberLLynchSYHeERipaS12-month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic painJ Opioid Manag201511433935626312961
PubMedGoogle Scholar
Prescription Drug Monitoring Program Training and Technical Assistance Center Guide No. 01–13Calculating Daily Morphine Milligram Equivalents (MMEs)Brandeis University2013 Available from: http://www.pdmpassist.org/pdf/BJA_performance_measure_aid_MME_conversion.pdfAccessed 26 April 2017
Google Scholar
RubinoMSummersKHPuenpatomAFuCOhsfeldtRLBen-JosephRHA comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tabletsJ Manag Care Pharm201117536737621657806
PubMed Web of Science ®Google Scholar